PRAXearnings
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- −$3.23Beat
- vs −$3.68 expected on Nov 9
- Stock move on it
- +19.94%
- one session
- Price
- $328.64
- −5.07% today · $7.47B cap
Past and upcoming reports
1
| Nov 9, 2026 | Sep 30, 2026 | Before the market opens | −$3.68 | Beat−$3.23 | +19.94% |
After the report
Nov 9, 2026 report
PRAX rose 20.12% after an EPS beat, but operating and guidance confirmation remained limited
PRAX reported third-quarter EPS of -$3.23 versus -$3.63 estimated, an 11.13% beat. Shares closed at $333.47, up $55.85 on 1.07 million shares, while no company-specific post-earnings news or guidance detail was provided. The next 30. 90 days require evidence that projected 26.84% next-year EPS growth is achievable.
Reported against expected
BeatReported EPS was -$3.23 versus -$3.63 estimated, a $0.40 positive surprise and 11.13% beat for the fiscal period ended September 30, 2026.
Guidance
No explicit company guidance or guidance update was provided in the payload. next-year EPS growth was forecast at 26.84%.
How the stock reacted
PRAX closed at $333.47 on November 9, up 20.12% or $55.85, with volume of 1,068,413 versus recent listed volumes below 400,000.
What changed
EPS was -$3.23, beating estimates by $0.40, while shares rose 20.12% to $333.47.
What the price now assumes
The volume-backed 20.12% rally prices greater confidence despite unavailable valuation multiples and incomplete operating data.
What it means for the business
Maintain a cautious positive bias. upgrade only if 26.84% forecast growth gains company-specific confirmation within 90 days.
The next one to three months, as we saw it then
Better case40%
The EPS beat converts into sustained confidence if projected 26.84% next-year growth receives operating or forecast confirmation.
Base case40%
The beat supports the shares, but absent guidance or post-earnings operating evidence, valuation and execution uncertainty keep the thesis unresolved.
Worse case20%
The rally retraces if the isolated EPS beat fails to support the projected growth trajectory or weak profitability remains unresolved.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Enter only after forecast growth remains at least 26.84% or company-specific evidence appears. do not trade if neither condition occurs.
Scenario odds are a judgement, not measured.